Figure 4. Effect of concomitant treatment with nucleoside transporter inhibitor NBMPR on TGN and adenine concentrations in ALL cells. (Left) Shown are intracellular TGN concentrations in CEM, Nalm-6, and MOLT-4 cells after treatment with MP in the presence or absence of nitrobenzylmercaptopurine ribonucleoside (NBMPR), a nucleoside transport (SLC29A1) inhibitor. (Right) Shown is the intracellular adenine concentration in CEM cells after incubation with adenine, in the presence or absence of NBMPR. Columns represent the averages of 3 independent experiments, each with 3 replicates; error bars represent range.
Figure 4.

Effect of concomitant treatment with nucleoside transporter inhibitor NBMPR on TGN and adenine concentrations in ALL cells. (Left) Shown are intracellular TGN concentrations in CEM, Nalm-6, and MOLT-4 cells after treatment with MP in the presence or absence of nitrobenzylmercaptopurine ribonucleoside (NBMPR), a nucleoside transport (SLC29A1) inhibitor. (Right) Shown is the intracellular adenine concentration in CEM cells after incubation with adenine, in the presence or absence of NBMPR. Columns represent the averages of 3 independent experiments, each with 3 replicates; error bars represent range.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal